EMG
TVRD

ETF Managers Group’s Tvardi Therapeutics TVRD Stock Holding History

ETF Managers Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,070
Closed -$6.57M – 691
2020
Q4 		$6.57M Sell
12,070
-5,905
-33% -$3.1M 0.14% 118
2020
Q3 		$8.23M Sell
17,975
-7,073
-28% -$4.11M 0.26% 101
2020
Q2 		$15.4M Buy
25,048
+607
+2% +$335K 0.55% 63
2020
Q1 		$11.6M Buy
24,441
+3,589
+17% +$1.95M 0.54% 65
2019
Q4 		$12.1M Buy
20,852
+1,091
+6% +$766K 0.42% 84
2019
Q3 		$13M Sell
19,761
-6,711
-25% -$5.58M 0.47% 72
2019
Q2 		$20.5M Buy
+26,472
New +$18.6M 0.65% 50
2019
Q1 		– Sell
-16,676
Closed -$7.62M – 585
2018
Q4 		$7.62M Buy
+16,676
New +$10.8M 0.36% 69
2018
Q3 		– Sell
-9,861
Closed -$75 – 622
2018
Q2 		$75 Buy
9,861
+486
+5% +$247K 0.01% 315
2018
Q1 		$3.99M Buy
9,375
+5,849
+166% +$2.84M 0.24% 79
2017
Q4 		$1.63M Buy
+3,526
New +$1.61M 0.12% 102

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

ETF Managers Group's TVRD Position: Q1 2021 in Review

ETF Managers Group sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 12,070 shares — an estimated $6.57M sold.

ETF Managers Group first reported a position in TVRD in Q4 2017 and held it in 11 quarters. The position peaked at $20.5M in Q2 2019. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • ETF Managers Group reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • ETF Managers Group sold 12,070 Tvardi Therapeutics shares in Q1 2021, an estimated $6.57M.
  • ETF Managers Group first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 11 quarters.
  • ETF Managers Group's Tvardi Therapeutics position peaked at $20.5M in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on ETF Managers Group's 13F filing for Q1 2021, filed 17 May 2021.